Biogenic amines in cerebrospinal fluid and plasma of patients with dementia of Alzheimer type.
The involvement of monoaminergic neurons in Dementia of Alzheimer Type (D.A.T.) is still a matter for debate. In a selected group of patients with D.A.T. we evaluated monoamine levels in cerebrospinal fluid (CSF) and plasma and found a significant decrease in serotonin and dopamine metebolite levels. Dopamine levels were reduced in both CSF and plasma. Moreover, a significant correlation was found between the duration of the illness and the decrease in monoamine levels. These findings suggest that there is systemic damage to monoaminergic neurons in D.A.T.
Pinessi
L
L
Department of Neurology, School of Medicine, University of Turin, Italy.
Rainero
I
I
De Gennaro
T
T
Gentile
S
S
Portaleone
P
P
Bergamasco
B
B
D000544:Alzheimer Disease / Q000097:blood / Q000134:cerebrospinal fluid*; D001679:Biogenic Amines / Q000097:blood / Q000134:cerebrospinal fluid*; D004298:Dopamine / Q000097:blood / Q000134:cerebrospinal fluid; D004837:Epinephrine / Q000097:blood / Q000134:cerebrospinal fluid; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood / Q000134:cerebrospinal fluid
D001679:Biogenic Amines; D004298:Dopamine; D009638:Norepinephrine; D006719:Homovanillic Acid; D004837:Epinephrine